Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Warner-Lambert

This article was originally published in The Tan Sheet

Executive Summary

Warner-Lambert: Reports completion of its purchase of Glaxo Wellcome's U.S. and European interest in the Warner Wellcome joint venture on July 1; the purchase originally was announced Dec. 19, 1995 ("The Tan Sheet" Jan. 1, p. 5). Purchase agreements totaling $150 mil. for Glaxo Wellcome interests in Canada, Mexico, Australia and New Zealand should be complete by third quarter 1996. The entire transaction will carry a $1.05 bil. pricetag and will bring "a variety of well-known OTC products, such as Sudafed, Actifed, Neosporin, and Nix, directly under the Warner-Lambert name," the company notes...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel